$EMR Cashflow Statement | Understand Stock

$EMR

$161.70 +$0.11 (0.07%) Close

$EMR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Sep 30, 2025	FY2024 12 months to Sep 30, 2024	FY2023 12 months to Sep 30, 2023	FY2022 12 months to Sep 30, 2022	FY2021 12 months to Sep 30, 2021
Operating activities
Net earnings
Earnings from discontinued operations, net of tax
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization
Stock compensation
Amortization of acquisition-related inventory step-up
Pension expense (income)
Pension funding
Gain on subordinated interest
Loss on Copeland note receivable
Changes in operating working capital
Gain on sale of business
Other, net
Cash from continuing operations
Cash from discontinued operations
Cash provided by operating activities

Investing activities
Capital expenditures
Purchases of businesses, net of cash and equivalents acquired
Divestitures of businesses
Proceeds from subordinated interest
Proceeds from related party note receivable
Other, net
Cash from continuing operations
Cash from discontinued operations
Cash provided by (used in) investing activities
Financing activities
Net increase (decrease) in short-term borrowings
Proceeds from short-term borrowings greater than three months
Payments of short-term borrowings greater than three months
Proceeds from long-term debt
Payments of long-term debt
Dividends paid
Purchases of common stock
AspenTech purchases of common stock
Payment of related party note payable
Purchase of noncontrolling interest
Repurchase of AspenTech share awards
Other, net
Cash used in financing activities
Effect of exchange rate changes on cash and equivalents
Increase (Decrease) in cash and equivalents
Beginning cash and equivalents
Ending cash and equivalents
Changes in operating working capital
Receivables
Inventories
Other current assets
Accounts payable
Accrued expenses

Comments